Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

Phase 2 Completed 12 enrolled University of Vermont

NaSingle-groupOpen-labelSupportive care

Summary

The purpose of this study is to evaluate the efficacy of methylnaltrexone in relieving opioid-induced constipation in cancer patients at various stages of disease.

Timeline

Start: 2009-10
Primary completion: 2013-12
Completion: 2013-12

Publications

Mori M, Ji Y, Kumar S, Ashikaga T, Ades S. Phase II trial of subcutaneous methylnaltrexone in the treatment of severe opioid-induced constipation (OIC) in cancer patients: an exploratory study. Int J Clin Oncol. 2017 Apr;22(2):397-404. doi: 10.1007/s10147-016-1041-6. Epub 2016 Sep 15.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Methylnaltrexone	Other / unclassified	0.15 mg/kg	Subcutaneous
Subject	Methylnaltrexone	Other / unclassified	8 mg	Subcutaneous
Subject	Methylnaltrexone	Other / unclassified	12 mg	Subcutaneous

Methylnaltrexone for Opioid-induced Constipation in Cancer Patients

Summary

Timeline

Publications

Drugs

Indications